DRW Securities’s PTC Therapeutics PTCT Stock Holding History

DRW Securities’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-4,100	Closed	-$249K	–	124
2015 Q1	$249K	Buy	+4,100	New	+$250K	0.04%	84

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

DRW Securities's PTCT Position: Q2 2026 in Review

DRW Securities sold out of PTC Therapeutics (PTCT) in Q2 2026, closing a stake of 18,169 shares — an estimated $1.24M sold.

DRW Securities first reported a position in PTCT in Q2 2025 and held it in 2 quarters. The position peaked at $1.24M in Q1 2026. 383 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

DRW Securities reported no remaining PTC Therapeutics position as of Q2 2026 after selling out during the quarter.
DRW Securities sold 18,169 PTC Therapeutics shares in Q2 2026, an estimated $1.24M.
DRW Securities first reported a position in PTC Therapeutics in Q2 2025 and held it in 2 quarters.
DRW Securities's PTC Therapeutics position peaked at $1.24M in Q1 2026.
383 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.